谷歌浏览器插件
订阅小程序
在清言上使用

Efficacy and Safety Results of CT-P41 (proposed Denosumab Biosimilar) Compared to Reference Denosumab in Postmenopausal Women with Osteoporosis: 78-Week Results from Phase 3 Randomized Controlled Trial

ARTHRITIS & RHEUMATOLOGY(2024)

引用 0|浏览1
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要